Form 4: DiaMedica Insider Boosts Stake by Over 1 Million Shares

DiaMedica Therapeutics director and 10% owner Jan Stahlberg, through Trill AB, significantly increased his beneficial ownership by purchasing over 1 million common shares in November 2025.

Summary

• Jan Stahlberg, a director and 10% owner of DiaMedica Therapeutics Inc., reported a series of common share purchases.
• The purchases were made indirectly through Trill AB, an entity where Jan Stahlberg is the sole owner and board member with sole voting and disposal power.
• A total of 1,061,277 common shares were acquired across seven transactions between November 17, 2025, and November 25, 2025.
• The transaction prices for these acquisitions ranged from $6.5166 to $8.5749 per share.
• Following these transactions, the beneficial ownership of common shares held by Trill AB, and indirectly by Jan Stahlberg, increased to 8,825,742 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged investment strategy.

Sentiment

Score: 8

Explanation: The significant insider buying by a director and 10% owner, totaling over $7.6 million, indicates strong confidence in the company's future. This is generally viewed very positively by the market.

Positives

• Significant insider buying by a director and 10% owner, Jan Stahlberg, through Trill AB, totaling 1,061,277 common shares.
• The purchases demonstrate strong conviction from a key insider, potentially signaling confidence in the company's future prospects.
• The transactions were executed under a Rule 10b5-1(c) plan, indicating a pre-planned investment strategy rather than opportunistic trading.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports insider transactions.

Risks

• No specific risks are mentioned in this Form 4 filing, which focuses solely on insider trading activity.

Future Outlook

This Form 4 filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Jan Stahlberg, as the board member and sole owner of Trill AB, has the sole power to vote and dispose of the reported shares.

Industry Context

Insider buying, especially by a significant shareholder and director, can be interpreted as a positive signal within the biotechnology and pharmaceutical industry, suggesting confidence in the company's drug pipeline, clinical trial progress, or market position. Such transactions often attract investor attention, particularly in sectors where future success is heavily reliant on R&D outcomes and regulatory approvals.

Comparison to Industry Standards

• Insider buying of this magnitude (over $7.6 million) by a director and 10% owner is a substantial investment, indicating strong conviction.
• While direct comparisons to specific companies or projects are not provided in this filing, such a move typically stands out among peer companies in the biotech sector, where insider transactions are closely watched for signals about future prospects, especially given the inherent risks and long development cycles.

Related Party Transactions

• The transactions involve Jan Stahlberg, a director and 10% owner, purchasing shares indirectly through Trill AB, an entity he solely owns and controls. This constitutes a related party transaction as it involves a key insider and an entity under their control.

Stakeholder Impact

• **Shareholders**: The significant insider buying could instill greater confidence among existing shareholders and attract new investors, potentially leading to increased demand for the stock.
• **Employees**: While not directly impacting employees, a strong signal of insider confidence can indirectly boost morale and perception of the company's stability and future.

Next Steps

• This filing does not explicitly mention any future actions, events, or milestones for the company or the reporting person beyond the reported transactions.

Key Dates

Recommendation

The substantial insider buying by Jan Stahlberg, a director and 10% owner, through Trill AB, totaling over 1 million shares and approximately $7.6 million, signals a very strong vote of confidence in DiaMedica Therapeutics Inc. This level of commitment from a key insider, especially under a Rule 10b5-1 plan, suggests management believes the stock is undervalued or expects significant positive developments. Such a strong insider signal often precedes positive performance and warrants a 'strong buy' recommendation for investors looking for companies with strong internal conviction.

Keywords

DiaMedica Therapeutics, DMAC, Insider Buying, Form 4, Jan Stahlberg, Trill AB, Share Purchase, Beneficial Ownership, Director, 10% Owner, Biotechnology, Pharmaceuticals